Entrectinib

Major

Entrectinib Sorafenib Nexavar An increased risk of QT interval prolongation Details Entrectinib Sotalol Betapace An increased risk of QT interval prolongation Details Entrectinib Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Entrectinib St John's Wort Reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Sulpiride An increased risk of QT interval prolongation Details Entrectinib Sultopride An increased risk of QT interval prolongation Details Entrectinib Suzetrigine Journavx Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Entrectinib Taletrectinib Ibtrozi Increased risk of QT interval prolongation and torsade de pointes Details Entrectinib Tamoxifen Nolvadex® An increased risk of QT interval prolongation Details Entrectinib Taurursodiol Decreased exposure of the CYP3A4 substrate Details Entrectinib Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Entrectinib Telaprevir Increased entrectinib exposure, increased frequency or severity of adverse reactions including increased risk of cardiac arrhythmi... Details Entrectinib Telavancin Vibativ An increased risk of QT interval prolongation Details Entrectinib Telithromycin Increased entrectinib exposure, increased frequency or severity of adverse reactions including increased risk of cardiac arrhythmi... Details Entrectinib Telotristat Ethyl Xermelo Reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Tetrabenazine Xenazine An increased risk of QT interval prolongation Details Entrectinib Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Entrectinib Tolterodine Detrol An increased risk of QT interval prolongation Details Entrectinib Toremifene Fareston An increased risk of QT interval prolongation Details Entrectinib Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Entrectinib Tramadol ConZip Increased traMADol exposure and an increased risk of seizures, serotonin syndrome and opioid toxicity Details Entrectinib Trazodone Raldesy An increased risk of QT interval prolongation Details Entrectinib Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Entrectinib Triclabendazole Egaten An increased risk of QT interval prolongation Details Entrectinib Trimipramine An increased risk of QT interval prolongation Details Entrectinib Triptorelin An increased risk of QT interval prolongation Details Entrectinib Trofinetide Daybue Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Entrectinib Troleandomycin Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Tucatinib Tukysa Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Vandetanib Caprelsa An increased risk of QT interval prolongation Details Entrectinib Vardenafil Levitra An increased risk of QT interval prolongation Details Entrectinib Vemurafenib Zelboraf An increased risk of QT interval prolongation Details Entrectinib Venetoclax Venclexta Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Entrectinib Venlafaxine An increased risk of QT interval prolongation Details Entrectinib Vepdegestrant Veppanu An increased risk of QT interval prolongation and an increased risk of torsade de pointes, polymorphic ventricular tachycardia, ot... Details Entrectinib Verapamil Calan Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Vilanterol An increased risk of QT interval prolongation Details Entrectinib Vinflunine An increased risk of QT interval prolongation Details Entrectinib Voclosporin Lupkynis An increased risk of QT interval prolongation Details Entrectinib Vonoprazan Voquezna Increased CYP3A substrates exposure Details